ARTICLE | Company News
FDA reviewing Mitsubishi's edaravone for ALS
August 30, 2016 7:00 AM UTC
Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) said FDA accepted an NDA for edaravone ( MCI-186) to treat amyotrophic lateral sclerosis (ALS). Its PDUFA date is June 16, 2017. ...